NIH Director's Blog: Drug Development

DECEMBER 15, 2020

Indeed, it shows that no matter your current experience with COVID-19, there are opportunities to get involved to develop vaccines and medicines that will help everyone. This registry is creating a list of potential volunteers willing to take part in ongoing or future NIH clinical trials focused on preventing COVID-19—like vaccines.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. We warmly congratulate this year’s winners.”

Immune Response 52

Immune Response Virus Disease Doctors 52

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. NH: This is the first single-cell resolution dictionary of each major immune cell type responding to each major cytokine in vivo at an unprecedented scale.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

Drug Discovery World

MAY 29, 2024

This is because ultimately, when it comes to what is going to be used for the patient, it is used as a bulk commodity, as we’ve seen more recently with things like vaccines. But the unpacked capsid can give rise to an immune response, which is not good for the patient.

Therapies 273

Therapies Molecular Biology DNA Immune Response 273

The Pharma Data

MARCH 16, 2021

TREMFYA is the first and only treatment approved for both adults with moderate to severe plaque PsO and for adults with active PsA that selectively inhibits IL-23, a cytokine that is a key driver of the inflammatory immune response associated with the symptoms of these chronic autoimmune diseases. TREMFYA was approved in the U.S.

Treatment 52

Treatment Pharmacokinetics Disease Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 24, 2020

24, 2020 – At least thee new COVID-19 vaccine candidates are already in the pipeline, will a roll-out expected early in the new year. “These are immune responses, so if you feel something after vaccination, you should expect to feel that. ” Another vaccine candidate. . TUESDAY, Nov. Meanwhile, U.S.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

Drug Discovery World

NOVEMBER 13, 2023

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

The Pharma Data

AUGUST 16, 2020

This means the immune system could remember how to fight Covid-19 even after original antibodies have faded. Indoor Biotechnologies is “hopeful” the test will help in vaccine development. Dr Hindley, whose PhD was in T cells, said: “They can live for a long time after the infection and give you that immune response.

Virus 52

Virus Vaccine Immune Response Government 52

The Pharma Data

APRIL 22, 2023

When the researchers switched the backbone of the Y-shaped antibody of one of the most common IgG antibodies in the blood, IgG1, to the backbone of a theoretically more potent antibody, IgG3, they saw a much stronger immune response. The studies were carried out in human cells and with mice.

Virus 40

Virus Immune Response Doctors Laboratories 40

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 130

Research Therapies Immune Response Clinical Trials 130

The Pharma Data

JANUARY 21, 2021

Doctors need better tools to evaluate the status of COVID-19 patients as early as possible because many of the treatments—such as monoclonal antibodies—are in short supply, and we know that some patients will get better without intensive treatments,” said co-senior author Andrew E. The research was published in the journal JCI Insight.

Research 52

Research DNA Vaccine Immune Response 52